The glymphatic system clears amyloid beta and tau from brain to plasma in humans.
Level 2 - randomized trial
Individual randomized crossover trial
PubMed 41593094 · doi:10.1038/s41467-026-68374-8
What was done
In a randomized crossover trial, 39 human participants underwent overnight monitoring during normal sleep versus sleep deprivation. Researchers used an investigational device to measure dynamic changes in synaptic-metabolic release and glymphatic activity, comparing observed plasma amyloid beta and tau levels against a multicompartment clearance model.
What was found
The abstract reports that normal sleep increased morning plasma concentrations of amyloid beta and tau compared to sleep deprivation, consistent with reduced parenchymal resistance and enhanced glymphatic clearance. The abstract reports no numerical values, effect sizes, or statistical significance levels.
Why it matters
This study provides experimental evidence in humans that sleep facilitates the clearance of Alzheimer's disease biomarkers from the brain to plasma via the glymphatic system.
Limits
The sample size is small (n = 39) and the abstract lacks quantitative values and effect sizes. Participant demographics and cognitive health status are not specified in the abstract, and measurements relied on an investigational device and computational modeling.